AstraZeneca Deal with Charles River Labs Worth at Least $30M

Oct 17 2012

Boston Business Journal

James C. Foster, Chairman, President and Chief Executive Officer of Charles River, said, “We are extremely pleased that AstraZeneca selected Charles River as its strategic in vivo biology partner. Utilizing our capabilities will enable AstraZeneca to create a flexible research platform to deliver innovative health solutions. Our shared passion for scientific excellence is a strong foundation for this relationship, and we look forward to working with AstraZeneca’s scientists ‘on the same side of the table’ to achieve their drug development goals."

Click here to read the full article.